A Cross-Reactive Protein Vaccine Combined with PCV-13 Prevents Streptococcus pneumoniae- and Haemophilus...

Area of Science:

• Microbiology and Immunology
• Vaccine Development
• Pediatric Infectious Diseases

Background:

• Acute otitis media (AOM) is a widespread childhood infection globally.
• Current vaccines against Streptococcus pneumoniae target capsular polysaccharides, leaving gaps in protection against non-encapsulated strains and un-covered serotypes.
• Mucosal infections like AOM persist despite existing vaccination strategies.

Purpose of the Study:

• To evaluate a novel protein-based vaccine for its efficacy against pneumococcal AOM.
• To assess the vaccine's protective effects against non-vaccine serotypes and its synergistic potential with existing vaccines.
• To determine the vaccine's ability to confer cross-protection against other otopathogens, including nontypeable Haemophilus influenzae.

Main Methods:

• Development of a fusion protein vaccine combining epitopes of CbpA with pneumolysin toxoid.
• Assessment of vaccine efficacy in protection models against pneumococcal AOM.
• Evaluation of antibody responses and cross-reactivity against multiple otopathogens.

Main Results:

• The protein-based vaccine demonstrated effective protection against pneumococcal AOM for non-PCV-13 serotypes.
• Co-administration with PCV-13 enhanced protection for PCV-13 serotypes.
• The fusion protein induced potent antibody responses against nontypeable Haemophilus influenzae and Streptococcus pneumoniae, providing protection against unencapsulated strains.

Conclusions:

• Augmenting current capsule-based vaccination with conserved, cross-reactive protein-based vaccines can broaden and enhance protection against AOM.
• This strategy offers a promising approach to combat prevalent childhood ear infections caused by diverse bacterial pathogens.
• The developed fusion protein vaccine shows potential for improved AOM prevention in children.